Combined therapy for intestinal dysbiosis as a strategy for the treatment of lipid metabolism disorders
DOI:
https://doi.org/10.63341/ijmmr/2.2025.26Keywords:
microbial composition, dyslipidaemia; probiotics, Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5Abstract
Dyslipidaemia, a major contributor to cardiovascular diseases, necessitates multifaceted treatment strategies.
This study aimed to evaluate the effectiveness of combined therapy – including probiotics, lifestyle modifications, and
dietary recommendations – in managing dyslipidaemia and its impact on gut microbiota composition. A total of 168
patients with dyslipidaemia were enrolled and categorised according to cardiovascular risk using the SCORE scale.
Group 1 included low-risk patients, while Group 2 comprised moderate-risk patients who also received simvastatin.
Both groups were prescribed a 12-week probiotic regimen containing Lactobacillus acidophilus LA-5 and Bifidobacterium
lactis BB-12, alongside recommendations for physical activity and cholesterollowering diets. Comprehensive assessments
of lipid profiles and gut microbiota composition were conducted before and after treatment. The results demonstrated
significant improvements in lipid profiles in both groups. Total cholesterol, low-density lipoprotein cholesterol, and
triglyceride levels decreased, while high-density lipoprotein cholesterol levels increased. Statistical analysis showed that
the differences in the percentage reductions of lipid profile parameters between the two groups were not statistically
significant (p > 0.05), confirming the potential impact of probiotic therapy on lipid levels. Analysis of the gut microbiota
revealed an increase in Bacteroidetes, and reductions in Firmicutes and Actinobacteria, along with a notable improvement
in the Firmicutes/Bacteroidetes ratio, indicating restored microbial balance. This study highlighted the potential of
probiotics as an effective adjunct in the management of dyslipidaemia, capable of complementing – or even reducing
dependence on – statin therapy. The findings support the integration of microbiota-targeted therapies into personalised
treatment strategies for dyslipidaemia
Received: 23.08.2025 | Revised: 01.12.2025 | Accepted: 30.12.2025
References
Pavlidou E, Fasoulas A, Mantzorou M, Giaginis C. Clinical evidence on the potential beneficial effects of probiotics
and prebiotics in cardiovascular disease. Int J Mol Sci. 2022;23(24):15898. DOI: 10.3390/ijms232415898
Oniszczuk A, Oniszczuk T, Gancarz M, Szymańska J. Role of gut microbiota, probiotics and prebiotics in the
cardiovascular diseases. Molecules. 2021;26(4):1172. DOI: 10.3390/molecules26041172
Banach K, Glibowski P, Jedut P. The effect of probiotic yogurt containing Lactobacillus Acidophilus LA-5 and
Bifidobacterium Lactis BB-12 on selected anthropometric parameters in obese individuals on an energy-restricted
diet: A randomized, controlled trial. Appl. Sci. 2020;10(17):5830. DOI: 10.3390/app10175830
Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human
intestinal microbiome. Nutrients. 2020;12(4):1107. DOI: 10.3390/nu12041107
Palaniyandi SA, Damodharan K, Suh JW, Yang SH. Probiotic characterization of cholesterol-lowering Lactobacillus
fermentum MJM60397. Probiotics Antimicrob Proteins. 2020;12(3):1161– 72. DOI: 10.1007/s12602-019-09585-y
Khare A, Gaur S. Cholesterol-lowering effects of Lactobacillus species. Curr Microbiol. 2020;77(4):638–44.
DOI: 10.1007/s00284-020-01903-w
Nechiporuk VM, Nebesna ZM, Kovalchuk ОV, Pentiuk LO, Korda MM. Ultrastructural changes in the liver in
experimental hyperhomocysteinemia on the background of hypo- and hyperthyroidism. Bull Med Biol Res.
;3(2):51–60. DOI: 10.11603/bmbr.2706-6290.2021.2.12339
Wongrattanapipat S, Chiracharoenchitta A, Choowongwitthaya B, Komsathorn P, La-Ongkham O, Nitisinprasert S,
et al. Selection of potential probiotics with cholesterol-lowering properties for probiotic yoghurt production. Food Sci
Technol Int. 2022;28(4):353–65. DOI: 10.1177/10820132211012252
Noori M, Shateri Z, Babajafari S, Eskandari MH, Parastouei K, Ghasemi M, et al. The effect of probiotic-fortified kefir
on cardiovascular risk factors in elderly population: A double-blind, randomized, placebo-controlled clinical trial.
BMC Nutr. 2024;10(1):74. DOI: 10.1186/s40795-024-00875-5
The World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human
Subjects [Internet]. [cited 2025 May 15]. Available from: https://surli.cc/ufjzge
Council of Europe. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to
the Application of Biology and Medicine: Convention on Human Rights and Biomedicine [Internet]. 1997 April 4
[cited 2025 May 15]. Available from: https://rm.coe.int/168007cf98
Order of the Ministry of Health of Ukraine No. 690. On Approval of the Procedure for Conducting Clinical Trials
of Medicinal Products and Expertise of Materials of Clinical Trials and the Model Regulation on Ethics Committees
[Internet]. 2009 September 23 [cited 2025 May 15]. Available from: https://zakon.rada.gov.ua/laws/show/z1010-
#Text
Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal
cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24(11):987–1003. DOI: 10.1016/s0195-
x(03)00114-3
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the
management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
DOI: 10.1093/eurheartj/ehz455
Mitchenko O, Lutai M. Recommendations for the diagnosis and treatment of dyslipidaemia. Kyiv: Ukrainian
Association of Cardiologists of Ukraine; Ukrainian Society of Atherosclerosis; 2020. 46 P.
Zhou S, Liu L, Ye B, Xu Y, You Y, Zhu S, et al. Gut microbial metabolism is linked to variations in circulating non-high
density lipoprotein cholesterol. EBioMedicine. 2024;104:105150. DOI: 10.1016/j.ebiom.2024.105150
Yan C, Bao J, Jin J. Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: A multiomics
Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver
disease. J Transl Med. 2024;22(1):179. DOI: 10.1186/s12967-024-04996-0
Flaig B, Garza R, Singh B, Hamamah S, Covasa M. Treatment of dyslipidemia through targeted therapy of gut
microbiota. Nutrients. 2023;15(1):228. DOI: 10.3390/nu15010228
Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut microbiota-derived TMAO: A causal
factor promoting atherosclerotic cardiovascular disease? Int J Mol Sci. 2023;24(3):1940. DOI: 10.3390/ijms24031940
Brown EM, Clardy J, Xavier RJ. Gut microbiome lipid metabolism and its impact on host physiology. Cell Host
Microbe. 2023;31(2):173–86. DOI: 10.1016/j.chom.2023.01.009
Roessler J, Leistner DM, Landmesser U, Haghikia A. Modulatory role of gut microbiota in cholesterol and glucose
metabolism: Potential implications for atherosclerotic cardiovascular disease. Atherosclerosis. 2022;359:1–12.
DOI: 10.1016/j.atherosclerosis.2022.08.018
Duan Y, Wang L, Ma Y, Ning L, Zhang X. A meta-analysis of the therapeutic effect of probiotic intervention in obese
or overweight adolescents. Front Endocrinol. 2024;15:1335810. DOI: 10.3389/fendo.2024.1335810
Kenny DJ, Plichta DR, Shungin D, Koppel N, Hall AB, Fu B, et al. Cholesterol metabolism by uncultured human gut
bacteria influences host cholesterol level. Cell Host Microbe. 2020;28(2):245–57. DOI: 10.1016/j.chom.2020.05.013
Lei L, Zhao N, Zhang L, Chen J, Liu X, Piao S. Gut microbiota is a potential goalkeeper of dyslipidemia. Front
Endocrinol. 2022;13:950826. DOI: 10.3389/fendo.2022.950826
Kappel BA, De Angelis L, Puetz A, Ballanti M, Menghini R, Marx N, et al. Antibiotic-induced gut microbiota depletion
exacerbates host hypercholesterolemia. Pharmacol Res. 2023;187:106570. DOI: 10.1016/j.phrs.2022.106570
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Khrystyna Kvit
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
